SC
ITCI

Sculptor Capital’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Sculptor Capital’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-105,000
Closed -$1.61M – 316
2020
Q1 		$1.61M Buy
+105,000
New +$2.28M 0.02% 139

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Sculptor Capital's ITCI Position: Q2 2020 in Review

Sculptor Capital sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2020, closing a stake of 105,000 shares — an estimated $1.61M sold.

Sculptor Capital first reported a position in ITCI in Q1 2020 and held it in 1 quarter. The position peaked at $1.61M in Q1 2020. 149 funds tracked by Wall St. Rank hold ITCI as of Q2 2020.

  • Sculptor Capital reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2020 after selling out during the quarter.
  • Sculptor Capital sold 105,000 Intra-Cellular Therapies Inc. shares in Q2 2020, an estimated $1.61M.
  • Sculptor Capital first reported a position in Intra-Cellular Therapies Inc. in Q1 2020 and held it in 1 quarter.
  • Sculptor Capital's Intra-Cellular Therapies Inc. position peaked at $1.61M in Q1 2020.
  • 149 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2020.

Based on Sculptor Capital's 13F filing for Q2 2020, filed 14 Aug 2020.